Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomization was performed by a person who was not a study interviewer or therapist using a SAS procedure and was stratified by patient performance status (self-reported ECOG scores 0 or 1 vs. 2) because this factor informs cancer treatment decision-making [33].”
From Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial (2018) · cites this paper as [33]
In the citing paper
“We are stratifying randomization by performance status because it is a key factor in MBC treatment decisions [28].”
From Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer (2020) · cites this paper as [28]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Research works printed but not linked: 1
- Network NCC. 2008. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2, ASCO-Edition 2008.
Cited by
Items 101–200 of 485
Toss, A., Venturelli, M., Peterle, C., Piacentini, F., Cascinu, S., & Cortesi, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010085 · Cited by 42
Upregulation of CCAT2 promotes cell proliferation by repressing the P15 in breast cancer
Deng, X., Zhao, Y., Wu, X., & Song, G. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.030 · Cited by 38
Dirix, L. Y., & Triebel, F. (2019) · Future Oncology · doi:10.2217/fon-2018-0807 · Cited by 38
Guerreiro, P. S., Corvacho, E., Costa, J. G., Saraiva, N., Fernandes, A. S., Castro, M., Miranda, J. P., & Oliveira, N. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12979 · Cited by 39
Masuda, N., Nishimura, R., Takahashi, M., Inoue, K., Ohno, S., Iwata, H., Mori, Y., Hashigaki, S., Muramatsu, Y., Nagasawa, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13507 · Cited by 37
Abdelhafez, O. M., Ahmed, E. Y., Latif, N. A. A., Arafa, R. K., Elmageed, Z. Y. A., & Ali, H. I. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.027 · Cited by 37
Bachelot, T., McCool, R., Duffy, S., Glanville, J., Varley, D., Fleetwood, K., Zhang, J., & Jérusalem, G. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2778-5 · Cited by 38
A review on metastatic breast cancer in Iran
Otaghvar, H. A., Hosseini, M., Tizmaghz, A., Shabestanipour, G., & Noori, H. (2015) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2015.02.001 · Cited by 43
Lindman, H., Wiklund, F. E., & Andersen, K. K. (2022) · BMC Cancer · doi:10.1186/s12885-022-10098-1 · Cited by 40
Emerging role of macrophages in non-infectious diseases: An update
Yousaf, H., Khan, M. I. U., Ali, I., Munir, M. U., & Lee, K. Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114426 · Cited by 39
Primary and secondary distant metastatic breast cancer: Two sides of the same coin
Güth, U., Magaton, I. M., Huang, D. J., Fisher, R. A., Schötzau, A., & Vetter, M. H. F. (2013) · The Breast · doi:10.1016/j.breast.2013.10.007 · Cited by 38
Pham, P. V., Le, H. T., Vu, B. T., Pham, V. Q., Le, P., Phan, N. L.-C., Trinh, V. N., Nguyen, H. T. L., Nguyen, S. T., Nguyen, T. L., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105239 · Cited by 35
Maeda, S., Saimura, M., Minami, S., Kurashita, K., Nishimura, R., Kai, Y., Yano, H., Mashino, K., Mitsuyama, S., Shimokawa, M., et al. (2017) · The Breast · doi:10.1016/j.breast.2016.12.017 · Cited by 34
Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
Attia, Y. M., Shouman, S. A., Salama, S. A., Ivan, C., Elsayed, A. M., Amero, P., Rodriguez‐Aguayo, C., & Lopez‐Berestein, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082974 · Cited by 36
Roda, E., Luca, F. D., Iorio, C. D., Ratto, D., Siciliani, S., Ferrari, B., Cobelli, F., Borsci, G., Priori, E. C., Chinosi, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103479 · Cited by 37
Kim, Y., Chung, Y. S., Park, E., Lee, S., & Lee, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-57515-y · Cited by 37
Harnessing the immune system in the battle against breast cancer
Nakasone, E. S., Hurvitz, S. A., & McCann, K. E. (2018) · Drugs in Context · doi:10.7573/dic.212520 · Cited by 35
Francken, A. B., Schouten, P. C., Bleiker, E. M. A., Linn, S. C., & Rutgers, E. J. T. (2013) · The Breast · doi:10.1016/j.breast.2013.07.045 · Cited by 44
Beebe, S. J., Celestine, M. J., Bullock, J. L., Sandhaus, S., Arca, J. F., Cropek, D. M., Ludvig, T. A., Foster, S. R., Clark, J. S., Beckford, F. A., et al. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110907 · Cited by 32
Radionuclide-Based Imaging of Breast Cancer: State of the Art
Li, H., Liu, Z., Yuan, L., Fan, K. S., Zhang, Y., Cai, W., & Lan, X. (2021) · Cancers · doi:10.3390/cancers13215459 · Cited by 35
“The European Society for Medical Oncology guidelines [34] recommend using 18F-FDG in early-stage breast cancer when conventional examination methods are inconclusive.”
BackgroundTuccari, G., Ieni, A., Barresi, V., Caltabiano, R., Zeppa, P., SORDO, R. D., Cabibi, D., Lanzafame, S., Sidoni, A., Franco, V., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s65294 · Cited by 32
Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing
Yang, H., Crosby, M., Walker, A., Wei, D. H., Leiker, K., & Weitao, T. (2017) · Journal of Cancer · doi:10.7150/jca.22554 · Cited by 36
Becker, J., Schwarzenböck, S. M., & Krause, B. J. (2020) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-42618-7_19 · Cited by 34
Breast cancer characteristics in low- and middle-income countries: An umbrella review
Tolentino-Rodriguez, L., Chkeir, M., Pofagi, V., Konga, I. A., Toniolo, J., Erazo, D., Preux, P., Blanquet, V., Vergonjeanne, M., & Parenté, A. (2025) · Cancer Epidemiology · doi:10.1016/j.canep.2025.102797 · Cited by 41
Wittayanukorn, S., Qian, J., Johnson, B., & Hansen, R. A. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215621150 · Cited by 30
Shi, J., Yang, N., Ding, H.-J., Zhang, J., Hu, M., Leng, Y., Han, X., & Sun, Y. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.04.016 · Cited by 30
Mudgway, R., Villanueva, C. C. D. P., Lin, A. C., Senthil, M., Garberoglio, C. A., & Lum, S. S. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08310-2 · Cited by 32
Generali, D., Venturini, S., Rognoni, C., Ciani, O., Pusztai, L., Loi, S., Jérusalem, G., Bottini, A., & Tarricone, R. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3453-9 · Cited by 28
Monteiro, I., Madureira, P., de Vasconscelos, A., Pozza, D. H., & de Mello, R. A. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.133 · Cited by 31
Ho, V. K. Y., Gijtenbeek, J. M. M., Brandsma, D., Beerepoot, L. V., Sonke, G. S., & der Loo, M. V. D. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.040 · Cited by 28
Monitoring in Metastatic Breast Cancer: Is Imaging Outdated in the Era of Circulating Tumor Cells?
Alunni‐Fabbroni, M., Müller, V., Fehm, T. N., Janni, W., & Rack, B. K. (2014) · Breast Care · doi:10.1159/000360438 · Cited by 30
He, M. Y., Liu, C., Shi, Q., Sun, Y., Zhang, Y., Xu, X., Yuan, H., Zhang, Y., Liu, Y., Liu, G., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0561 · Cited by 29
Liu, Y., Wu, J., Ji, Z., Chen, L., Zou, J., Zheng, J., Lin, W., Cai, J., Chen, Y., Zheng, D., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11322-2 · Cited by 32
“Among these subtypes, hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) BC are the most common, accounting for 60–65% of patients with metastatic or advanced BC [3, 6, 7].”
BackgroundBody, J., Pereira, J., Sleeboom, H. P., Maniadakis, N., Terpos, E., Acklin, Y. P., Fínek, J., Gunther, O., Hechmati, G., Mossman, T., et al. (2015) · The European Journal of Health Economics · doi:10.1007/s10198-015-0716-7 · Cited by 34
Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
Wu, S., He, Z., Ren, H., Yang, L., Sun, J., Li, F.-Y., Guo, L., & Lin, H. (2015) · Journal of Cancer · doi:10.7150/jca.13090 · Cited by 28
Keshtvarz, M., Salimian, J., Yaseri, M., Bathaie, S. Z., Rezaie, E., Aliramezani, A., Norouzbabaei, Z., Amani, J., & Douraghi, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0008 · Cited by 28
Tasleem, S., Bolger, J. C., Kelly, M. E., Boland, M. R., Bowden, D. J., Sweeney, K., & Malone, C. M. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1746-9 · Cited by 28
Hourcade‐Potelleret, F., Lemenuel‐Diot, A., McIntyre, C., Brewster, M., Lum, B., & Bittner, B. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.63 · Cited by 28
Latest biopsy approach for suspected metastases in patients with breast cancer
Niikura, N., Odisio, B. C., Tokuda, Y., Symmans, W. F., Hortobágyi, G. N., & Ueno, N. T. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.182 · Cited by 28
Claus, J., Patel, G. S., Ng, T., & Parker, P. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140043 · Cited by 29
Borrelli, P., Donswijk, M. L., Stokkel, M. P. M., Teixeira, S. C., van Tinteren, H., Rutgers, E. J. T., & Olmos, R. A. V. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3545-8 · Cited by 27
Spaich, S., Kinder, J., Hetjens, S., Fuxius, S., Gerhardt, A., & Sütterlin, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00535 · Cited by 27
McCormack, P. L. (2013) · Drugs · doi:10.1007/s40265-013-0109-0 · Cited by 29
Differentiating the Causes of Spontaneous Rib Fracture After Breast Cancer
Harris, S. R. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.07.001 · Cited by 26
Deng, J., Thennavan, A., Shah, S. M., Bagdatlioglu, E., Klar, N. J., Heguy, A., Marier, C., Meyn, P., Zhang, Y., Labbe, K. E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05936-4 · Cited by 26
Fabi, A., Giannarelli, D., Malaguti, P., Ferretti, G., Vari, S., Papaldo, P., Nisticò, C., Caterino, M., Vita, R. D., Mottolese, M., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s89575 · Cited by 26
Giordano, C., Rovito, D., Barone, I., Mancuso, R., Bonofiglio, D., Giordano, F., Catalano, S., Gabriele, B., & Andò, S. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.01.006 · Cited by 27
Zhao, Y., Liu, H., Ying, W., Wang, C., Yu, Y., Sun, W., & Liu, J.-F. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7591 · Cited by 28
Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications
Hadjipanteli, A., Doolan, P., Kyriacou, E. C., & Constantinidou, A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s252801 · Cited by 26
Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients
Boloori, A., Saghafian, S., Chakkera, H. A., & Cook, C. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142363 · Cited by 25
Koleva‐Kolarova, R., Oktora, M. P., Robijn, A. L., Greuter, M. J. W., Reyners, A. K. L., Buskens, E., & de Bock, G. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.001 · Cited by 25
Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
Beauchemin, C., Cooper, D., Yelle, L., Lachaîne, J., & Lapierre, M.-È. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s63302 · Cited by 25
Incoronato, M., Mirabelli, P., Catalano, O. A., Aiello, M., Parente, C., Soricelli, A., & Nicolai, E. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-356 · Cited by 25
Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer
Nicolini, A., Ferrari, P., & Rossi, G. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_13 · Cited by 25
Brufsky, A. (2015) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s31586 · Cited by 31
A structured review of health utility measures and elicitation in advanced/metastatic breast cancer
Cook, J. W., Wolfram, V., & Hao, Y. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s100448 · Cited by 30
Molecular imaging using PET and SPECT for identification of breast cancer subtypes
Liu, H., Chen, Y., Wu, S., Song, F., Zhang, H., & Tian, M. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000576 · Cited by 26
Kurosky, S. K., Mitra, D., Zanotti, G., & Kaye, J. A. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.10.008 · Cited by 25
“Treatment guidelines indicated chemotherapy should be considered among patients with visceral crisis.(3) Although approximately two-thirds of the patients had visceral disease at the”
BackgroundInfluentialReal-World Patient- and Caregiver-reported Outcomes in Advanced Breast Cancer
Lambert-Obry, V., Laliberté, A. G., Castonguay, A., Zanotti, G., Tran, T. C., Mates, M., Lemieux, J., Chabot, P., Prady, C. C. M., Couture, F., et al. (2018) · Current Oncology · doi:10.3747/co.25.3765 · Cited by 24
Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism
Zuo, Q., Park, N. H., Lee, J. K., & Madak‐Erdogan, Z. (2022) · Nutrients · doi:10.3390/nu14122376 · Cited by 29
Tan, Y., Zhang, W., Huang, Z. K., Tan, Q., Zhang, Y., Wei, C., & Feng, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-66658-x · Cited by 24
“…the necessity for confirmation through imaging studies such as MRI, CT scans, or functional imaging like positron emission tomography-computed tomography, dynamic contrast-enhanced magnetic resonance imaging, or magnetic resonance diffusion-weighted imaging when clinical suspicion exists 15 .”
Wynne, C., Ellis-Pegler, R. B., Waaka, D., Schwabe, C., Lehle, M., Heinzmann, D., Mangat, R., Li, C., Dick, A. E., Cranshaw, N. A., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2273-z · Cited by 25
Radiotherapy in patients with distant metastatic breast cancer
Steinauer, K. K., Gross, M. W., Huang, D. J., Eppenberger‐Castori, S., & Güth, U. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-126 · Cited by 24
Durán, I., Fink, M., Bahl, A. K., Hoefeler, H., Mahmood, A., Lüftner, D., Ghazal, H., Wei, R., Chung, K., Hechmati, G., et al. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12452 · Cited by 24
Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
Piva, R., Ticconi, F., Ceriani, V., Scalorbi, F., Fiz, F., Capitanio, S., Bauckneht, M., Cittadini, G., Sambuceti, G., & Morbelli, S. D. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s111098 · Cited by 25
Regulatory role of microRNAs in cancer through Hippo signaling pathway
Astamal, R. V., Maghoul, A., Taefehshokr, S., Bagheri, T., Mikaeili, E., Derakhshani, A., Delashoub, M., Taefehshokr, N., Isazadeh, A., Hajazimian, S., et al. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153241 · Cited by 23
Sesto, M. E., Carroll, C. B., Zhang, X., Chen, K., Terhaar, A., Wilson, A. S., & Tevaarwerk, A. J. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06755-z · Cited by 25
Sini, V., Cinieri, S., Conte, P., Laurentiis, M. D., Leo, A. D., Tondini, C. A., & Marchetti, P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.008 · Cited by 26
Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.
Cheuk, I., Shin, V. Y., Siu, M. T., Tsang, J. Y., Ho, J. C. W., Chen, J., Tse, G. M.-K., Wang, X., & Kwong, A. (2015) · PubMed · Cited by 25
Yu, Y., Hong, H., Wang, Y., Fu, T., Chen, Y., Zhao, J., Chen, P., Cai, R., Tan, Y., He, Z., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09650-3 · Cited by 23
Escribà, J. M., Pareja, L., Esteban, L., Gálvez, J., Melià, A., Roca, L., Clèries, R., Sanz, X., Bustins, M., Pla, M. J., et al. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-587 · Cited by 22
Tehrani, S. S., Gharibi, S., Movahedpour, A., Goodarzi, G., Jamali, Z., Khatami, S. H., Maniati, M., Ranjbar, M., Shabaninejad, Z., Savardashtaki, A., et al. (2020) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2020.1812640 · Cited by 22
“However, these drugs have many drawbacks including their large molecular size and immunogenicity.([43]) Thus, antibody or antibody fragment was conjugated to the toxic, forming immunotoxins, which can increase specificity, efficacy, and potency of anti-HER2 antibody.”
BackgroundPenault-Llorca, F. M., Coudry, R. A., Hanna, W. M., OSAMURA, R. Y., Rüschoff, J., & Viale, G. (2013) · The Breast · doi:10.1016/j.breast.2012.12.004 · Cited by 23
P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice
Vieira, A. F., Dionísio, M. R., Gomes, M., Cameselle‐Teijeiro, J., Lacerda, M., Amendoeira, I., Schmitt, F. C., & Paredes, J. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.232 · Cited by 23
Watanabe, J., Ito, Y., Ohsumi, S., Mizutani, M., Tashiro, H., Sakurai, K., Takahashi, M., Saito, T., Tsurutani, J., Mukai, H., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0486-4 · Cited by 21
Alamri, A., Rauf, A., Khalil, A. A., Alghamdi, A., Alafnan, A. D., Alshammari, A., Alshammari, F., Malik, J. A., & Anwar, S. (2021) · BioMed Research International · doi:10.1155/2021/9734279 · Cited by 25
“7 percent in emerging economies (269,000 deaths), respectively [2].”
BackgroundEvaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer
Ciruelos, E., & Jackisch, C. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.883922 · Cited by 21
Poletti, P. L., Ghilardi, V., Livraghi, L., Milesi, L., Caremoli, E. R., & Tondini, C. A. (2014) · Future Oncology · doi:10.2217/fon.13.251 · Cited by 21
Marshall, E., Bertaut, A., Desmoulins, I., Darut‐Jouve, A., Ponnelle, T., Poillot, M., Beltjens, F., & Arveux, P. (2016) · The Breast Journal · doi:10.1111/tbj.12717 · Cited by 24
“Breast cancer (BC) is the most frequent cancer in women in Western countries and is still the leading cause of cancer death in women (1).”
BackgroundSwitching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
Gligorov, J., Curigliano, G., Müller, V., Knoop, A. S., Jenkins, V. A., Verma, S., Osborne, S., Lauer, S., Machackova, Z., Fallowfield, L. J., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.05.004 · Cited by 23
Self-citationSong, W., Thakor, P., Vesey, D. A., Gobe, G. C., & Morais, C. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.126 · Cited by 23
Management of leptomeningeal metastasis in breast cancer
Assi, H. I., Mahmoud, T., Saadeh, F. S., & Darsa, H. E. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.07.001 · Cited by 26
Circulating tumour cells: telling the truth about metastasis
Cristofanilli, M. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70091-9 · Cited by 21
Reinhardt, F., Franken, A., Fehm, T. N., & Neubauer, H. J. (2017) · Tumor Biology · doi:10.1177/1010428317731511 · Cited by 22
Ancillary Tests in Breast Cytology: A Practical Guide
de Beça, F. F., & Schmitt, F. C. (2019) · Acta Cytologica · doi:10.1159/000499697 · Cited by 20
Elfgen, C., Güth, U., Gruber, G., Birrer, S., Bjelic‐Radisic, V., Fleisch, M. C., & Tausch, C. (2020) · Breast Cancer · doi:10.1007/s12282-020-01114-y · Cited by 20
Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines
Joy, A. A., Ghosh, M., Fernandes, R., & Clemons, M. J. (2015) · Current Oncology · doi:10.3747/co.22.2360 · Cited by 20
HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer
Verma, S., Joy, A. A., Rayson, D., McLeod, D., Brezden‐Masley, C., Boileau, J.-F., & Gelmon, K. A. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0217 · Cited by 21
Long non-coding RNAs as novel biomarkers for breast cancer invasion and metastasis
Zhang, K., Luo, Z., Zhang, Y., Song, X., Zhang, L., Wu, L., & Liu, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6462 · Cited by 19
Mokrim, M., Aftimos, P. G., Errihani, H., & Piccart, M. J. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-203647 · Cited by 20
Koleva‐Kolarova, R., Greuter, M. J. W., van Kruchten, M., Vermeulen, K. M., Feenstra, T., Buskens, E., Glaudemans, A. W. J. M., de Vries, E. F. J., de Vries, E. F. J., Hospers, G. A. P., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.138 · Cited by 19
Raphael, J., & Verma, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3342-2 · Cited by 19
State of the Art in 2022 PET/CT in Breast Cancer: A Review
Zhang-Yin, J. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030968 · Cited by 26
Polastro, L., Aftimos, P. G., & Awada, A. H. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.920693 · Cited by 19
Incidental extra-mammary findings in breast MRI
Alduk, A. M., Prutki, M., & Štern-Padovan, R. (2015) · Clinical Radiology · doi:10.1016/j.crad.2015.01.003 · Cited by 19
Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer
Manso, L., Moreno, F., Márquez, R. M., Castelo, B., Arcediano, A., Arroyo, M., Ballesteros, A. I., Calvo, I., Echarri, M. J., Enrech, S., et al. (2015) · Current Oncology · doi:10.3747/co.22.2210 · Cited by 19
The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7
Liu, Z.-G., Tang, J., Chen, Z., Zhang, H., Wang, H., Yang, J., & Zhang, H. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3604 · Cited by 19
Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer
Labidi, S., Mejri, N., Lagha, A., Daoud, N., Benna, H. E., Afrit, M., & Boussen, H. (2016) · Breast Care · doi:10.1159/000452194 · Cited by 19
Claessens, A. K. M., Bos, M. E. M. M., López‐Yurda, M., Bouma, J. M., Rademaker-Lakhai, J. M., Honkoop, A. H., de Graaf, H., van Druten, E. B., van Warmerdam, L. J. C., van der Sangen, M. J. C., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4906-8 · Cited by 21
Venema, C. M., de Vries, E. F. J., van der Veen, S. J., Dorrius, M. D., van Kruchten, M., Schroder, C. P., Hospers, G. A. P., & Glaudemans, A. W. J. M. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0549-y · Cited by 20
Metadata
- Authors
- Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E.
- Affiliations
- European School of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Gdańsk Medical University (PL)
- Corresponding author
- Senkus, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 23
- Pages
- vii11-vii19
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4234749243
- Cited by
- 485
- References
- 40
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 30 · 2020: 37 · 2019: 41 · 2018: 33 · 2017: 53 · 2016: 42 · 2015: 66 · 2014: 49 · 2013: 32 · 2012: 1
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2625 d)
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- locally recurrent breast cancer, metastatic breast cancer, breast cancer diagnosis, breast cancer treatment, breast cancer follow-up, incidence, mortality, early detection, adjuvant systemic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.